cyrilzakka/clinical-trials huggingface dataset:
One Million Cancer Treatment Months

The OMCAT Register aims to provide learning databases in cancer comprising both PRO data using PRO-React and "ground truth" (outcome data verified by the physician during patient examinations). Intelligent learning and knowledge engineering procedures will utilize this PRO data to provide high-quality event prediction algorithms. The ground-truth data enables so-called "supervised learning" techniques of artificial intelligence, because predicted events can be verified with a high level of certainty from ground-truth data.

The next generation of PRO-React by CANKADO is designed to predict impending incident threats at an earlier stage than previously feasible and -- by more timely intervention -- help physicians to eliminate or mitigate the severity of an unfavourable event, reduce the required intensity of countermeasures, or otherwise reduce patient risks.

A highly reliable identification of situations classified as "low-risk" by CANKADO could also enable a more focused utilization of resources as well as enhanced patient comfort and decreased stress, e.g., due to less frequent monitoring visits or reduced need for invasive diagnostics.

The OMCAT Register aims to provide learning databases in cancer comprising both PRO data using PRO-React and "ground truth" (outcome data verified by the physician during patient examinations). Intelligent learning and knowledge engineering procedures will utilize this PRO data to provide high-quality event prediction algorithms. The ground-truth data enables so-called "supervised learning" techniques of artificial intelligence, because predicted events can be verified with a high level of certainty from ground-truth data.

The PRO data of a patient provide what is known in engineering, physics, and statistics as "time series" of observations. The unique feature of PRO time series for applications in cancer is the very high "sampling frequency" (e.g., daily or better) compared to examinations, which generally occur at fixed, and much less frequent intervals. Prediction algorithms based on PRO data would thus be ideally suited to reduce the delay in detecting events, for example, by triggering physician appointments or indicating the need for more intensive medical diagnostics.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Age ≥ 18 years
* Diagnosed with cancer
* Prescribed CANKADO PRO-React Onco

Exclusion Criteria:

* Lack of consent to study participation or lack of patient's ability to consent
* Enrolled in this trial within a further treatment
Text Message Reminders for Hearing Healthcare

Many individuals with hearing loss do not receive adequate hearing healthcare. Given their close and long-term relationships with patients, primary care providers (PCPs) could play a vital role in improving access to hearing healthcare. Unfortunately, hearing loss is often underdiagnosed in primary care settings, because hearing screening is not a routine part of primary care visits, and the responsibility often falls on the patient or family to recognize and address the issue. The investigators propose to pilot test the use of text message reminders to encourage elderly patients to discuss hearing assessment with there PCPs. The study objectives are to: 1) design an automated text-messaging reminder system; 2) assess the feasibility of deploying the intervention in a clinical trial setting; and 3) evaluate whether the intervention increases willingness to seek hearing healthcare.


Eligibility Criteria:
Inclusion Criteria:

* English-speaking adult patients aged 65 and older
* Have not audiometric testing within the past 5 years
* Has had at least one prior visit encounter with a Stanford primary care provider the past 1 year
* Has a cell phone with a valid phone number

Exclusion Criteria:

* History of childhood hearing loss
* Hearing aid users
* Limited English proficiency
Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study

A Multi-Centre, Multi-country, Randomized, Double-Blind (Subject, Investigator), Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma

Eligibility Criteria:
Inclusion Criteria:

* history of asthma for ≥ 6 months
* taking inhaled corticosteroids
* non-smoking
* Baseline (pre-bronchodilator) FEV1 35-80% predicted at screening.
* Reversible airways disease as indicated by an increase of FEV1 ≥12% from baseline after nebulised salbutamol or albuterol.
* symptomatic according to the ACQ-7

Exclusion Criteria:

* Unstable severe asthma
* Recent respiratory illness
* Presence of other respiratory disease or chronic pulmonary condition other than asthma
* Treatment with omalizumab within 4 months of study
* Recent gastrointestinal or respiratory parasitic infestation
* History of severe allergy to food or drugs

Other protocol-defined inclusion/exclusion criteria may apply
Blood Pressure Self Management for Hypertension & Prehypertension Using an Internet Enabled, Automated Self Management Program

The specific aim of the study is to assess the impact of an Internet-enabled, automated, self-management program on blood pressure control of employees of a large local company.

We propose to conduct a randomized controlled trial of an Internet-enabled, automated self-management program. The study will be carried out through six local sites (offices) of a large employer. 3 sites will be intervention sites and 3 will be control sites.

Subjects enrolled from the intervention sites will receive a blood pressure meter and access to an Internet site where they can view their readings, read educational material regarding hypertension management and receive personalized tips and feedback.

Subjects enrolled from the control sites will have access to a blood pressure monitor located at their workplace but will only be provided with basic written information about hypertension at the start of the trial and will receive no feedback.

The trial will run for 6 months from the time of enrollment and the primary outcome measure will be a change in systolic blood pressure.

Eligibility Criteria:
Inclusion Criteria:

* Full-time employees of EMC
* Aged 30 to 65 years at time of enrollment
* Any of the following
* A diagnosis of hypertension as defined by one of the following
* Taking an antihypertensive medication
* Being told at least twice by a physician or other health professional that the subject has high blood pressure†
* A BP \> 140/90 detected at screening by the research team on 2 separate occasions.
* A diagnosis of prehypertension as defined by a systolic BP between 120-139 or a diastolic BP between 80-89 detected at screening by the research team on 2 separate occasions
* Access to the Internet at work and / or at home

Exclusion Criteria:

* Inability to self-monitor blood pressure due to musculoskeletal or cognitive impairment
* Known secondary cause of hypertension e.g. renal artery stenosis, Cushing's disease.
Prevalence, Awareness, Attitudes and Patterns of Stimulant Drug Use Among Students in Egyptian Universities

Stimulants are dangerous drugs that are commonly abused by individuals looking to stay alert and focused, lose weight, stay awake, and get high. Although these drugs can be extremely harmful and even life-threatening, many of them can also be used to treat conditions like ADHD, narcolepsy, and in some cases, depression. There are many types of stimulant drugs, and it can be beneficial to know a little about each one, its purposes, and how harmful it can be when abused.

Illicit stimulants are usually schedule II, depending on whether or not they can be used to treat medical conditions. While some variations of stimulants are schedule I drugs, most are extremely addictive and dangerous schedule II substances. These drugs are often abused in a binge-crash pattern. According to the NIDA Teen, "In order to keep the 'high' going, people may take the drug repeatedly within a short period of time, at increasingly higher doses." This makes these drugs extremely addictive.

The aim of this survey to detect prevalence of non prescription stimulants in Egyptian students and increase their awareness of the harmful effects of these drugs.

Methodology Undergraduate students at a large public university in Egypt (Minia, Assuit, Souhag, South Valley) who were 18 years of age or older took the survey in 2024. All survey and recruitment materials were approved by Minia University, faculty of pharmacy.

Students will receive survey through email. Students took the survey online at a time and location of their choice. No time limit was imposed. Participants will automatically routed through each section of the survey. First, students read a description of the study, including potential benefits and costs of taking the survey, and then they will be asked if they are a current undergraduate student at the participating university and their age. First section included the demographic data of participants, the second section the investigator will aske participants to indicate if they had ever been prescribed a stimulant. If participant answered yes, participants will route to the next section which asks about the frequency of use, the effects of stimulants and any complain if present.

Eligibility Criteria:
Inclusion Criteria:

- Academic student Age (18-30) years Included in medical faculty

Exclusion Criteria:

* Not undergraduates student Aged \< 18 years
Respiratory Muscle Strength in Different Age Groups

In determining respiratory muscle strength, mouth pressure measurement is most frequently used in the clinic. Determination of respiratory muscle strength loss provides benefits such as taking the decision to use individual rehabilitation methods, making the decision for extubation in patients with mechanical ventilation. But Turkey normative values, these values are not available. In the investigator's country, the respiratory muscle forces of the cases are evaluated by comparing them with the normal / expected values of the Scandinavian races that do not have similar anatomical features with the Turkish society, which causes errors in diagnosis.

The 250 healthy cases, whose age ranges are between 20-70, 20-29, 30-40, 40-49, 50-59 and 60-70, will be examined by a pulmonologist and asked if they have any disease that may affect respiratory muscle strength. Mouth pressure measurements will be made for healthy and inclusion criteria, and maximal inspiratory and expiratory pressure distributions will be examined.


Eligibility Criteria:
Inclusion Criteria:

* The age range is 20-70,
* Body mass index to be 18.0- 29.5 kg / m2
* No cardiac, neuromuscular or endocrine disease that may affect any respiratory muscle strength Respiratory function parameters to be normal,
* Not being a smoker

Exclusion Criteria:

* Not agreeing to participate in the study
* Not being able to adapt to the device
Vaginal Misoprostol Before Intrauterine Contraceptive Device Insertion

the current study was conducted to assess efficacy of vaginal misoprostol before IUD insertion following previous insertion failure


Eligibility Criteria:
Inclusion Criteria:

One previous failed attempt of IUD insertion.

Exclusion Criteria:

1. Uterine fibroid distorting the cavity.
2. Anatomical uterine abnormality with distortion of the cavity
3. Current pelvic inflammatory disease or recently treated pelvic inflammatory disease (PID) in the last three months.
4. Current purulent cervicitis (chlamydia or gonorrhea).
5. Immediately after septic abortion.
6. Uterus size less than 6 cm and more than 9 cm.
Dynamic Hyperinflation In Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients

Chronic obstructive pulmonary disease is a common respiratory condition that is characterized by inflammation of the large and small peripheral airways , the alveoli and adjacent capillary networks. Severe airflow obstruction that imposes a significant load on the respiratory system is a major manifestation of Chronic obstructive pulmonary disease. The reduced expiratory airflow also causes air trapping at the end of expiration , producing alveolar pressure that are higher than atmospheric pressure before the next breath. This condition is intrinsic positive end-expiratory pressure .


Eligibility Criteria:
Inclusion Criteria:

* patient with acute exacerbation of Chronic obstructive pulmonary disease and respiratory failure who are intubated and mechanically ventilated.

Exclusion Criteria:

* patient with neuromuscular diseases.
* patient with pulmonary vascular diseases e.g pulmonary embolism.
BOTOX® Prophylaxis in Patients With Chronic Migraine

This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic migraine.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of chronic migraine
* Willing to use BOTOX® as preventative treatment for migraine

Exclusion Criteria:

* None
Performance Thresholds Evaluation by Wet Injection Quantification and Magnetic Resonance Imaging (MRI) of Subcutaneous and Intramuscular Injections (0,65ml) of Several Configurations of Needle-free Devices (ZENEO®)

The aim of this study is to evaluate the performance of the ZENEO needle free device in subcutaneous functioning limits (low performance limit and high performance limit) and for intramuscular injections.


Eligibility Criteria:
Inclusion Criteria:

* male or female healthy volunteers aged between 18 and 60 years,
* affiliated to or covered by the French social security system,
* BMI between ≥20 and ≤30 kg/m²
* Patients without chronic medical or surgical illness
* Patients with normal clinical examination at the screening visit,
* Patients with normal blood pressure at the screening visit: systolic BP \< 140 mmHg and diastolic BP \< 90 mmHg, determined with the patient seated and resting for at least 5 minutes,
* Patients within normal range values for the following laboratory tests (appendix I) unless the investigator considers an abnormality to be clinically irrelevant (to be documented and agreed with the sponsor before inclusion) within 1 month prior to the start of the study (only for MRI sub study volunteers),
* Absence of cannabis, opiate, cocaine, amphetamine history (only for MRI sub study volunteers)

Exclusion Criteria:

* history of drug abuse
* history of hypersensitivity (disease or drug)
* treatment with platelet inhibiting drugs within one week before inclusion
* treatment with anticoagulant within four weeks before inclusion
* subject likely to take any medication during the study
* contra-indication to MRI: metallic intra-corporeal devices, claustrophobia
* prior participation to other interventional clinical research within 3 months
* in custody due to administrative or legal decision or under tutelage or being admitted in a sanitary or social institution.
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.


Eligibility Criteria:
Inclusion Criteria:

* Patient has mild to moderate Alzheimer's disease
* Patient has been receiving a stable dose of an acetylcholinesterase inhibitor
* Patient has a MMSE score between 12 and 26
* Patient has a MHIS score of less than or equal to 4
* Females must be postmenopausal for at least two years or surgically sterile
* Patient has an identified, reliable, caregiver who will support him/her to ensure compliance with treatment and will accompany them to each outpatient visit

Exclusion Criteria:

* Patient is living in a nursing home
* Patient has a history of any significant neurologic disease other than Alzheimer's disease
* Patient has any uncontrolled medical illness
* Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence
Carbohydrate Quality and Its Impact on Athletic Enjoyment and Burnout

This study aimed to evaluate the effect of carbohydrate quality on enjoyment of physical activity and burnout in athletes. Data were collected from 139 active athletes aged 19 to 35 years using a Demographic Structure Questionnaire, the Athlete Burnout Questionnaire (ABQ), and the Physical Activity Enjoyment Scale (PACES). Carbohydrate quality was assessed using food frequency data, and the results were analyzed with SPSS 24 software.

Objective: The aim of this study was to evaluate the effect of carbohydrate quality on enjoyment of physical activity and burnout in athletes.

Method: A total of 139 active athletes aged 19 to 35 years participated in the study. Participants completed a Demographic Structure Questionnaire, the Athlete Burnout Questionnaire (ABQ), and the Physical Activity Enjoyment Scale (PACES). To assess carbohydrate quality, food frequency data were collected, and scores were based on fiber intake, the whole-to-total grain ratio, glycemic index, and solid-to-total carbohydrate ratio, each evaluated on a scale from 1 to 5 points. The resulting scores were categorized into five quartiles, with Q5 indicating the highest and Q1 the lowest carbohydrate quality. Data were analyzed using SPSS 24 software.

Eligibility Criteria:
Inclusion Criteria:

* Only athletes who are actively participating in sports
* Age range of 19 to 35 years
* Voluntary participation

Exclusion Criteria:

-Individuals engaging in irregular physical activity
STEMI and Incretins Treatment

ST elevation myocardial infarction (STEMI) patients affected by multivessels coronary artery stenosis, represent a clinical relevant problem. The management and prognosis of these patents are supported by few literature data. Therefore, in this study authors enrolled real world diabetic vs. non diabetic patients admitted for STEMI and associated to multi vessels coronary disease. Then these diabetics were divided in incretin users (6 months of incretin treatment before study enrollment) vs. never incretin users. In these patients authors studied all cause mortality, cardiac mortality, and major adverse cardiac events at 12 months follow up.

ST elevation myocardial infarction (STEMI) patients affected by multivessels coronary artery stenosis represent a class of patients really challenging to treat. In fact, treatment, clinical management, and prognosis are supported by few literature data. Therefore, in this study authors enrolled real world patients admitted for STEMI and associated to multi vessels coronary disease. Multivessels (Mv) coronary stenosis were characterized by non obstructive coronary stenosis (NOCS) as coronary lesions \<50% with fractional flow reserve \> 0.8. Therefore, STEMI was treated by percutaneous coronary intervention by primary angioplasty and direct stenting (DES stenting) of culprit vessel lesion. Then these STEMI-Mv-NOCS patients were divided in diabetics vs. non diabetics, and received conventional full medical therapy for STEMI. Then these diabetics were divided in incretin users (6 months of incretin treatment before study enrollment) vs. never incretin users. Study outcomes were all cause mortality, cardiac mortality, and major adverse cardiac events at 12 months follow up. Authors studied these study outcomes comparing diabetics vs. non diabetics at 12 moths follow up, and diabetics incretin-users vs. never-incretin-users.

Eligibility Criteria:
Inclusion Criteria:

aged \>18, first STEMI, STEMI with multi vessels coronary stenosis.

Exclusion Criteria:

aged \< 18, renal impairment, mono vessel STEMI, severe depression of left ventricle ejection fraction (LVEF \<35%).
A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.

This study will evaluate the efficacy and safety of Tamiflu in patients with clinically-diagnosed influenza occurring during an influenza outbreak within the community. Patients will be randomized to receive Tamiflu 75mg bid orally plus support therapy (NSAIDs and antibiotics) or support therapy alone. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility Criteria:
Inclusion Criteria:

* adult patients, 18-64 years of age;
* ambulatory;
* influenza-like illness;
* positive rapid assay for detection of influenza antigen.

Exclusion Criteria:

* presentation \>36h after onset of symptoms;
* influenza-like symptoms outside an outbreak based on local surveillance activities;
* influenza vaccination between November 2006 and January 2007;
* receipt of antiviral therapy, systemic steroids or immunosuppressants within 2 weeks prior to study day 1.
Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part II

The overall hypothesis is that plastic bags used in combination with WHO thermoregulation care will reduce the incidence of hypothermia in preterm/low birth weight and full term infants when compared to routine WHO thermoregulation care alone. Part II is for preterm/low birth weight infant with or without plastic head cover used from 1 hour after birth until discharge or 24 hours after birth to assist with temperature regulation.

Due to limited resources, hospitals in the developing world struggle to provide sufficient incubators and to maintain climate-controlled nurseries. Therefore, premature low birth weight infants continue to be at an increased risk of hypothermia throughout their hospitalizations. This study will compare the incidence of hypothermia in preterm/low birth weight infants randomized to receive WHO thermoregulation care (control groups) or WHO thermoregulation care and a plastic bag covering their torsos and lower extremities (intervention group) starting at one hour after birth and continued to discharge or 24 hours after birth, whichever occurs first. The axillary temperature of each infant will be taken one hour after birth, every subsequent 3-4 hours, and at discharge or 24 hours after birth when infants will be removed from the plastic bags. Seizures, hyperthermia, room temperature, and death will be recorded throughout the hospitalization for all infants. With an estimated baseline hypothermia rate of 50% and a hypothesized 20% absolute risk reduction (40% relative risk reduction), a sample size of 182 will be used to have a power of 80% and a confidence interval of 95%.

Eligibility Criteria:
Inclusion Criteria:

* Estimated gestational age 29-36 6/7 weeks or birth weight 1400-2500g
* Delivery in the hospital

Exclusion Criteria:

* Infant admitted to the NICU
* Birth weight less than 1400 gms
* Abdominal wall defect or myelomeningocele
* Major congenital anomalies
* Blistering skin disorder